Hepatic Insulin Resistance and Whole-Body Outcomes
A special issue of Livers (ISSN 2673-4389).
Deadline for manuscript submissions: closed (25 October 2021) | Viewed by 486
Special Issue Editors
Interests: heme oxygenase; bilirubin; oxidative stress; nuclear receptors; fatty liver; glucocorticoid receptor; PPARs
Special Issues, Collections and Topics in MDPI journals
2. Diabetes Institute, Heritage College of Osteopathic Medicine, Ohio University, Athens, OH 45701-2979, USA
Interests: diabetes; hypertension; insulin resistance; metabolism; metabolic diseases; physiology
Special Issues, Collections and Topics in MDPI journals
Interests: liver development and disease; gene regulation; transcriptional regulation; liver cancer
Interests: obesity; diabetes; hypertension; cardiovascular disease; heme oxygenase; bilirubin; biliverdin reductase; antioxidants
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Non-alcoholic fatty liver disease (NAFLD) has risen worldwide in parallel to the rise in obesity and metabolic syndrome. Metabolic syndrome is marked by insulin resistance and is manifested in part by altered insulin and lipid metabolism. The liver is a major site of insulin clearance that, together with insulin secretion, determines the systemic insulin level that regulates insulin’s action in peripheral tissues. Dysregulation of this process leads to hepatic and systemic insulin resistance, type 2 diabetes, and its cardiovascular complications.
This Special Issue focuses on the central role that the liver plays in regulating insulin and fat metabolism, and how this may interact with adipocytes to regulate whole-body insulin sensitivity and cardiovascular functions.
Dr. Terry D. Hinds
Prof. Dr. Sonia Michael Najjar
Dr. Brett Spear
Dr. David E. Stec
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Livers is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Insulin resistance
- Insulin clearance
- Hyperinsulinemia
- Non-alcoholic fatty liver disease
- Non-alcoholic steatohepatitis
- Intraabdominal adiposity
- Atherosclerosis
- Hypertension
